
SCARD Pool report for 01-01-2000 to 31-12-2000

Participants	Doctors	6	
	Patients	48	
Specimens	New lesions	146	82.02%
	Previously biopsied lesions	32	17.98%
	Total lesions	178	100.00%

Breakdown of new versus previously biopsied specimens



Percentage of new lesions tested which were malignant	75.91%
Percentage of Definitively excised lesions that were malignant	77.69%
Lesions tested to find one melanoma (NNT)	2.43
Percentage of lesions tested for NMSC which were NMSC	79.03%
Ratio of New BCCs : New Melanomas	10:1

Accuracy

Diagnostic sensitivity

Melanomas	100.00% of 7
All NMSC	93.88% of 98
BCCs	94.29% of 70
SCCs	40.74% of 27

Positive predictive value

Melanomas	63.64% of 11
All NMSC	82.88% of 111
BCCs	59.46% of 111
SCCs	73.33% of 15

Adequacy

Percentage of definitively managed malignant cases where surgical margins were adequate


BCC	57.14% of 14
IEC/Bowens disease	0% of 0
SCC	100.00% of 4
Keratoacanthoma	0% of 0
Melanoma - in situ	100.00% of 3
Melanoma - invasive	50.00% of 2
Melanoma - invasive > 1mm	100.00% of 1
Other malignant	0% of 0

© 2026 SCARD Systems Pty Ltd

Lesion Breakdown

Histological Diagnosis

BCC (unspecified type)	37	24.67%
BCC - Superficial	17	11.33%
BCC - Nodular/Solid	13	8.67%
BCC - Aggressive	3	2.00%
IEC/Bowens disease	21	14.00%
SCC	6	4.00%
Keratoacanthoma	0	0%
Pinkus Fibroepithelioma	0	0%
Merkel cell tumour	0	0%
Other malignant	0	0%
NMSC Metastasis	0	0%
Melanoma - in situ	3	2.00%
Melanoma - invasive	2	1.33%
Melanoma - invasive > 1mm	2	1.33%
Melanoma - metastasis	0	0%
MELTUMP	1	0.67%
Naevus - other	0	0%
Naevus - dysplastic/Clark	0	0%
Naevus - blue	1	0.67%
Naevus - Spitz/Reed	0	0%
Naevus - Compound	0	0%
Solar keratosis	17	11.33%
Solar lentigo	0	0%
Seborrhoeic keratosis	3	2.00%
Lentigo Simplex	0	0%
Lichenoid keratosis (LPLK)	1	0.67%
Dermatofibroma	0	0%
Sebaceous gland hyperplasia	2	1.33%
Benign cyst	0	0%
Other benign	8	5.33%
Histology Pending	4	2.67%



© 2026 SCARD Systems Pty Ltd

Procedures

Definitive Surgical Management used to exclude melanoma

Ellipse	3	75.00%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	1	25.00%
Curettage & Cautery	0	0%
Liquid N2 freeze/thaw	0	0%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	0	0%
Other	0	0%

Biopsy used to exclude melanoma

Punch - sample	4	28.57%
Shave - sample	1	7.14%
Incisional	0	0%
Punch - removal	5	35.71%
Shave - removal	0	0%
Excisional	4	28.57%
Curettage	0	0%
Other	0	0%

Breakdown of definitive management procedures for malignant conditions

Ellipse	24	18.32%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Curettage & Cautery	93	70.99%
Liquid N2 freeze/thaw	0	0%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	1	0.76%
GP referral	0	0%
Specialist referral	13	9.92%
Other	0	0%

Breakdown of definitive management procedures for benign conditions

Ellipse	1	9.09%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	2	18.18%
Liquid N2 freeze/thaw	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	0	0%
Other	0	0%

© 2026 SCARD Systems Pty Ltd

Procedures (continued)


Percentage of procedures/closures that were complex

Complex Closures	0% of 3
Complex Closures (inc Curettage & Cautery)	0% of 11

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

Nose	5	29.41% of 17
Lip	0	0% of 1
Ear	0	0% of 2
Eyelid	0	0% of 1
Other face	0	0% of 35
Scalp	0	0% of 4
Neck	0	0% of 6
Shoulder	0	0% of 8
Chest	0	0% of 3
Abdomen	0	0% of 1
Genitalia	0	0% of 0
Back	0	0% of 20
Buttock	0	0% of 0
Arm	0	0% of 8
Forearm	2	8.70% of 23
Hand Dorsal	0	0% of 5
Hand Palmar	0	0% of 0
Finger Dorsal	0	0% of 0
Finger Nail	0	0% of 0
Finger Palmar	0	0% of 0
Thigh	0	0% of 3
Leg	0	0% of 9
Foot Dorsal	0	0% of 0
Foot Plantar	0	0% of 0
Toe Dorsal	0	0% of 0
Toe Nail	0	0% of 0
Toe Plantar	0	0% of 0
Palm Or Sole	0	0% of 0



© 2026 SCARD Systems Pty Ltd